Evogene calls shareholder vote on Pure Capital nominees to reconstitute board under cooperation deal

• Evogene reached a cooperation deal with activist investor Pure Capital Group to settle disputes tied to the Sept. 4 shareholder meeting vote.
• Pure Capital had challenged the published voting results, then warned it would launch a special tender offer under Israeli law.
• Agreement resets board control: two directors already resigned, replaced by Pure Capital nominees, subject to shareholder approval within 42 days.
• Shareholders will also vote on adding two more Pure Capital nominees, replacing two outgoing directors, shifting the board to a 4-3 split.
• Pure Capital withdrew the tender-offer notice, accepted a 60-day standstill; Evogene paused share issuance, excluding routine employee grants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061600PR_NEWS_USPR_____LN64970) on October 06, 2026, and is solely responsible for the information contained therein.